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Abstract: Ataxia in children is a common clinical sign of numerous neurological disorders consisting
of impaired coordination of voluntary muscle movement. Its most common form, cerebellar ataxia,
describes a heterogeneous array of neurologic conditions with uncountable causes broadly divided
as acquired or genetic. Numerous genetic disorders are associated with chronic progressive ataxia,
which complicates clinical management, particularly on the diagnostic stage. Advances in omics
technologies enable improvements in clinical practice and research, so we proposed a multi-omics
approach to aid in the genetic diagnosis and molecular elucidation of an undiagnosed infantile
condition of chronic progressive cerebellar ataxia. Using whole-exome sequencing, RNA-seq, and
untargeted metabolomics, we identified three clinically relevant mutations (rs141471029, rs191582628
and rs398124292) and an altered metabolic profile in our patient. Two POLR1C diagnostic variants
already classified as pathogenic were found, and a diagnosis of hypomyelinating leukodystrophy
was achieved. A mutation on the MMACHC gene, known to be associated with methylmalonic
aciduria and homocystinuria cblC type, was also found. Additionally, preliminary metabolome
analysis revealed alterations in our patient’s amino acid, fatty acid and carbohydrate metabolism.
Our findings provided a definitive genetic diagnosis reinforcing the association between POLR1C
mutations and hypomyelinating leukodystrophy and highlighted the relevance of multi-omics
approaches to the disease.
Keywords: cerebellar ataxia; diagnosis; genomics; transcriptomics; metabolomics; hypomyelination;
leukodystrophy; POLR1C
1. Introduction
Ataxia in children is a common clinical sign of numerous neurological disorders con-
sisting of impaired coordination of voluntary muscle movement that cannot be attributed
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to muscle weakness [1]. Ataxia usually involves disorders affecting the cerebellum, the
vestibular system or peripheral sensory nerves, and these can be acute, intermittent or
progressive. Most of the chronic or progressive disorders are consequent to degenerative
and metabolic diseases [1,2].
The most frequent form of ataxia—cerebellar ataxia—is caused by damage to, or
the dysfunction of, the cerebellum as a result of diverse disease processes. Cerebellar
ataxia is a clinically heterogeneous group of disorders that typically manifest with poor
coordination, unsteady, staggering gait, limb incoordination (dysmetria), slurred speech
(dysarthria), difficulty swallowing (dysphagia), and abnormal eye movements, but it can
also exhibit a wide range of phenotypes both in clinical features and in age of onset [1].
This condition is especially devastating for children because they are still developing motor
skills [3]. Although the causes of ataxia are countless, they can be broadly divided into
two groups: acquired, such as infection or tumor, and hereditary or genetic, such as ataxia
telangiectasia [4]. The temporal course of the disorder and the family history are key
elements in distinguishing acquired from possible genetic causes [5].
Hereditary cerebellar ataxias are a group of highly heterogeneous disorders, but
each usually follows a typical autosomal dominant, autosomal recessive, X-linked or
mitochondrial inheritance [5]. Overall, the prevalence of childhood hereditary ataxia
in Europe is estimated at approximately 15/100,000 children [6]. Autosomal recessive
cerebellar ataxias (ARCAs), with usual onset in childhood, occur more frequently than
autosomal dominant cerebellar ataxias (ADCAs), typically having adult onset; which
means that recessive causes of ataxia are more common in children. Despite the greater
frequency of ARCAs, many of the cases remain not fully characterized and go genetically
undiagnosed [7].
There are numerous disease-causing genes currently known for hereditary cerebellar
ataxias; however, in spite of the rapid growth of molecular research in childhood pre-
sentation of ataxia, diagnostic genetic testing is still difficult owing to the large amount
of relatively uncommon subtypes with phenotypic overlap [5]. In addition, cerebellar
ataxia is associated with a diverse constellation of neurological features, often overlapping
with systemic manifestations, and may also be a major or significant part of the clinical
portrait in nearly 300 additional genetic conditions [8,9]. This enormous medical and
genetic heterogeneity dramatically complicates clinical management, particularly on the
diagnostic stage [10].
Identifying the underlying cause of cerebellar ataxia is a daunting but crucial task [1].
When a diagnosis is accurate and made in a timely manner, a patient has the best oppor-
tunity for a positive health outcome [11]. Although few causes of inherited childhood
cerebellar ataxia can be treated, making a precise diagnosis is vital for potential thera-
pies, prognostic counseling, and accurate genetic counseling among others [2,12,13]. The
diagnostic assessment of a child with cerebellar ataxia is clinically challenging because
it requires experience and a methodical approach using detailed clinical evaluation and
appropriate investigations [1].
Following detection on a neurological examination of typical clinical signs of ataxia
and after the exclusion of non-genetic causes, meticulous and comprehensive investigations
to find a genetic cause are required [1]. Unfortunately, in many cases the etiology of ataxia
remains uncertain despite a complete workup, and as a result a diagnostic odyssey often
begins for these children. This process takes years, imposes heavy economic costs and may
not lead to a definitive molecular diagnosis [14].
Advances in omics technologies—genomics, transcriptomics or metabolomics—are
promoting a paradigm shift in biomedical science and have ushered in a new era of preci-
sion medicine. These technologies can be applied to get a picture of the underlying biology
of a disease at a resolution never before seen, and falling costs are now enabling their use
in clinical practice and research [15]. Individually, these technologies have contributed
to remarkable medical advances that have begun to enter clinical practice. For instance,
broadly popular genome and exome sequencing are being progressively incorporated into
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clinical care, and being used to aid diagnoses, particularly of rare diseases [16–18]. While
the introduction of these tools in genetic testing has improved the diagnostic yield for
genetic ataxias [4], the majority of cases cannot be solved by these technologies alone: a
multidisciplinary and combined approach is ultimately needed [15].
Here, we propose exome, transcriptome and metabolome studies to aid in the diag-
nosis and molecular elucidation of a child presenting with chronic progressive cerebellar
ataxia and an undiagnosed condition. Altogether, the results obtained reinforce the associa-
tion between POLR1C mutations and hypomyelinating leukodystrophy [19–22] as well as
the importance of multi-omics approaches to disease.
2. Results
2.1. Case Report
Our patient was a Spanish girl born to non-consanguineous healthy parents after an
uneventful pregnancy and delivery. She had one healthy sister. There were no similar cases
in her family, but her father suffered from anxiety and various tics.
When the patient was 2.5 years old, her parents sought medical attention, and a clinical
examination revealed tremors, nystagmus, dysmetria and an unsteady gait. Then she
subsequently developed progressive ataxia, dysarthria, spasticity and generalized dystonia,
requiring the use of a wheelchair at 5 years of age. The patient also exhibited myopia
and started wearing glasses at the same age. At age 7, she presented with dysphagia to
liquids that worsened over time. At age 8, she experienced a febrile seizure, and treatment
with levetiracetam was started, achieving complete control of seizures until the age of 14.
Tremors improved after treatment with propranolol. Cognition appeared largely spared
and her dentition was normal.
A complete metabolic study of blood and urine yielded normal results. Electroen-
cephalography (EEG) recording and nerve conduction velocities revealed no findings of
relevance. Visual evoked potentials showed a delayed left P100 wave with bilateral re-
duced amplitude. Somatosensory evoked potentials were altered in lower limbs. Auditory
brainstem response was normal. Electromyography (EMG) confirmed a non-epileptic
myoclonus on a deltoid muscle. Magnetic resonance imaging (MRI) of the brain showed
diffuse supratentorial and cerebellar white matter hyperintensities on T2-weighted images.
Optic radiations were spared. T1 sequence showed diffuse isointensity in the supratentorial
white matter suggesting a hypomyelinating process. A thin corpus callosum and cerebellar
atrophy (progressive) were also observed (Figure 1). The patient progressively worsened,
which accelerated in adolescence, presenting with severe dysphagia (eventually requiring
a gastrostomy tube at 14 years old) and more autonomic seizures. She died at 15 from a
respiratory tract infection.
The differential diagnosis of known progressive ataxias with leukoencephalopathy
included mitochondriopathies, ceroid lipofuscinosis, sialidosis, GM2 gangliosidosis, Nie-
mann Pick type-C disease, and PLA2G6-associated neurodegeneration. The cerebrospinal
fluid (CSF) lactate analysis was normal. The muscle biopsy showed a slight deficit of
redox complex I and I + III. The Filipin test was normal and NPC1 gene sequencing was
negative, which excluded a diagnosis of Niemann Pick type-C disease. DNA extracted from
peripheral blood was sent for sequencing at a hospital. No pathogenic variants were found.
Alternatively, high-resolution chromosomal analyses using the whole-genome NimbleGen
CGX cytogenetics array (Roche, Basel, Switzerland) by Imegen (Valencia, Spain) revealed
a deletion within 16p12.2 (with genomic coordinates chr16:21479157–21647056; GRCh37)
of about 0.168 Mb, encompassing genes METTL9, IGSF6, and OTOA. The deletion was
classified as being of uncertain clinical significance and was not described before; how-
ever, similar deletions in the region had already been described in the general population,
suggesting it could be a rare polymorphism. Apart from the OTOA gene, known to be
associated with an autosomal recessive form of deafness [23], the other genes involved
in the deletion had not been previously associated with any medical condition. No other
potentially pathogenic losses or gains in other chromosome regions were identified except
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for known copy number variations (CNVs). In addition, dentatorubral–pallidoluysian
atrophy (DRPLA) genetic testing by Lorgen G.P. (Granada, Spain) revealed CAG repeat ex-
pansions in the atrophin-1 (ATN1) gene within the normal range for the patient, sister and
both parents (with 10–18 CAG repeats). Also, mitochondrial DNA analysis of the patient
yielded no variants related to mitochondrial diseases apart from one variant (m.1725C>T)
not previously described in the literature.
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2.2. Whole-Exome Analysis
To investigate the etiology and aid in the diagnosis of this unexplained case, next-
generation, whole-exome sequencing (WES) was performed on the patient, both parents
and her sister. During the process of identifying the causal genes, variants were filtered
by frequency <2% and by type (synonymous variants, non-coding intronic, UTR vari-
ants). Missense variants, loss of function variants, nonsense and frameshift mutations,
splice-site alterations, loss of stop codons, non-synonymous substitutions, and codon
insertions and deletions were selected. Variants were then prioritized using values of
consequence type, SIFT [24], PolyPhen [25], CADD [26], REVEL [27], MetalLR [28] and
MutationAssessor [29]. Sequence analysis revealed (i) two heterozygous variants in the
POLR1C gene (RNA polymerase I and III subunit C), rs141471029 (c.193A>G; p.Met65Val)
in the patient and her mother, and rs191582628 (c.836G>A; p.Arg279Gln) in the patient
and her father, and (ii) a heterozygous variant on the MMACHC gene (the metabolism of
cobalamin associated C), rs398124292 (c.271dup; p.Arg91LysfsTer14), in the patient and her
father. The unaffected sibling did not present any of the 3 mutations found in our patient
(rs141471029, rs191582628 and rs398124292). These three variants were validated using
Sanger sequencing. Both mutations on POLR1C induced a missense variation, whereas the
one in MMACHC resulted in a frameshift variant. Variants were all already registered in
the 1000 Genomes Project database, the Single Nucleotide Polymorphism database and the
Genome Aggregation Database (gnomAD) [30]. According to the gnomAD database: (i)
only 214 out of 251,490 alleles (frequency of allele G = 0.000851) carried the rs141471029
mutation but never in a homozygous state, (ii) only 51 out of 251,432 alleles (frequency of
allele A = 0.000203) carried rs191582628 but never in a homozygous state, and (iii) only
290 out of 249,456 alleles (frequency of allele dupA = 0.001163) carried rs398124292. In
the European (non-Finnish) population (gnomAD_exome), variant allele frequencies were
G = 0.001521 (173/113770), A = 0.000217 (28/129186), and AA = 0.001602 (206/128612)
respectively. An in silico pathogenicity assessment performed with PolyPhen-2 [25] and
SIFT [24] predicted these variants to be deleterious (pathogenic or likely pathogenic). Both
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missense variants found at POLR1C—a gene that encodes a subunit common to RNA poly-
merases I (POLR1) and III (POLR3)—affect amino acids that are conserved through species,
and have been known to be associated with Treacher Collins syndrome (TCS) [31] and
hypomyelinating leukodystrophies [19–22]. Furthermore, the variant found at MMACHC
predicts a change of the arginine residue at position 91 to lysine resulting in a frameshift
and a premature stop codon. It is also known to be associated with methylmalonic aciduria
and homocystinuria cblC type (MAHCC) [32]. The exact function of the protein encoded
by this gene is not known, but it is postulated that it could have a role in the binding and
intracellular trafficking of cobalamin or vitamin B12 [33].
2.3. Transcriptome Analysis
To further explore the potential pathogenic role of these mutations, we performed next-
generation transcriptome sequencing (RNA-seq) on the patient skin-fibroblast culture, and
a human foreskin fibroblast cell culture (HEF line) that served as the control. We compared
gene expression as a way to find genes that were differentially expressed between our
patient and those of the control. The abnormally expressed genes in our patient can be
found in Supplementary Table S1. We found that the candidate genes were within the
group of expression outliers—both genes were upregulated. The patient had a 9.5-fold
increase in POLR1C transcript expression (the logarithm base 2 of the fold change, log2FC
= 3.244) and a 43-fold increase in MMACHC transcript expression (log2FC = 5.424) as
compared to the control. Increases were validated through quantitative Real-Time Reverse
Transcription PCR (RT-PCR) in blood samples from healthy controls. In addition, we set up
RT–PCR analyses to study the effect of the variation among the patient and her unaffected
family members. Results showed that mRNA levels of POLR1C (p < 0.0001) and MMACHC
(p < 0.0025) were up-regulated in the patient when compared with the controls (Figure 2).
Regarding the differential expression of POLR1C in the patient and her family members,
both mother (p < 0.0001) and sister (p < 0.0371) showed significantly lower expression when
compared with the patient. On the other hand, the father had higher expression than the
mother and sister but similar to that of the patient. Although the gene expression of the
father was lower than that of the patient, no statistical differences were found (Figure 3).
No malignant isoforms were detected in the patient or any family member studied.
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Figure 2. RT–PCR analysis of mRNA expressions of POLR1C and MMACHC in the patient and the
control. mRNA expression was determined by RT–PCR is calculated as a ratio relative to GAPDH
and expressed relative to the controls. Error bars represent standard deviation (SD). ***, p < 0.0001;
**, p < 0.01.
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Figure 3. RT–PCR analysis of mRNA expressions of POLR1C in the patient and her unaffected family
members. mRNA expression determined by RT–PCR is calculated as a ratio relative to HPRT1 and
expressed relative to her parents and sibling. (E2), (E3), and (E7) indicate the different primers
used to analyze expression of POLR1C. Error bars represent standard deviation (SD). ***, p < 0.0001;
*, p < 0.05; ns, not significant.
2.4. Metabolome Analysis
Using untargeted metabolomic protocols to analyze plasma and urine samples of the
patient, a total of 89 and 201 metabolites with known chemical structures were identified,
respectively (Supplementary Tables S2 and S3). The levels of 74 plasma metabolites and
187 urine metabolites were increased in the patient compared to the control, while the rest
were decreased.
Results from plasma showed that within the phosphatidic acid (PA), phosphatidyl-
choline (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS) groups, all
metabolites identified, except for PC (14:0) and PS (40:5), were elevated when compared
with the control, in a range of log2FC 1.5 to 5.6. In addition, within the carnitine pool,
all metabolites detected were increased, most of them in a range of log2FC 1.5 to 3.1)
and one, the 3-Hydroxy-cis-5-tetradecenoylcarnitine, to a higher degree (log2FC = 11.8).
In the organic acids group, increased levels of lactic acid (log2FC = 2.5) and fatty acids
(log2FC = 1.5–3.4) were found in the patient. With respect to the amino acids profile, the lev-
els of alanine, L-glutamine, asparagine, tryptophan and N-Methyl-L-Proline were increased
(log2FC = 1.5–2.6), whereas the levels of arginine (log2FC = −1.7), cystine (log2FC = −2.9)
and N6-Methyl-L-lysine (log2FC = −16.4) were decreased. Also, two tripeptides were de-
tected with slightly increased levels in the patient as compared with the control. A mild de-
crease was found in two carbohydrate metabolites, pyranose and furanose (log2FC = −1.6).
The levels of serotonin (log2FC = 1.9), glycerol (log2FC = 1.7), urea (log2FC = 1.6), and
bilirubin (log2FC = 1.8) were also inc ased.
Urine results showed an acylcarnitine profile n the pat ent where ll de ected metabo-
lites but one wer increased, most in a range of log2FC 2.1 to 6.2) except for decadienoyl-
carnitine with log2FC = 9.1, and where the 3-hydroxy−5, 8-tetra ecadiencarnitine level
was decreased (log2FC = −3). PE (22:6) was lower (log2FC = −2.6) than in the co trol.
Regarding amino acids metabolism, it should be noted that the level of N-acetyltryptophan
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was substantially higher (log2FC = 9.7), whereas the levels of cystine (log2FC = −1.7),
lysine (log2FC = −1.8), and taurine (log2FC = −2.5) were lower in the patient compared
with the control. With respect to the organic acids group, most metabolites detected
showed levels between log2FC = 1.5 and log2FC = 5.5 except for the 6-hydroxy-7E,9E-
octadecadiene-11,13,15,17-tetraynoic acid (log2FC = 7.5) and the 3-hydroxyhippuric acid
(log2FC = 7.6). The levels of isopentenyladenine-9-N-glucoside (log2FC = 9.5), (1R,3S,4S,6R)-
6,9-dihydroxyfenchone 6-O-b-D-glucoside (log2FC = 9.2), and sulfotrehalose (7,5) were
highly increased, whereas the levels of methylsalicylate O-[rhamnosyl-(1->6)-glucoside]
(log2FC = −1.5), sedoheptulose (log2FC = −1.7), 2-methoxyacetaminophen sulfate (log2FC = −2.7),
and 3-methyl-1-phenyl-3-pentanol (log2FC = −3) were decreased in the patient.
3. Discussion
We reported on a Spanish patient with POLR1C hypomyelinating leukodystrophy.
Leukodystrophy due to POLR1C mutation is exceptionally rare; so far, only 26 such
patients have been reported worldwide [19–22]. Demographic, genetic, clinical, and
radiological characteristics of our patient and those of all published cases are summarized in
Tables 1–3. In our patient, cerebellar ataxia, tremor and dystonia were the most prominent
and severe symptoms.
Clinical and radiological characteristics of our case were compatible with hypomyeli-
nating leukodystrophy due to mutations on the POLR1C gene. Hypomyelinating leukodys-
trophies are a group of heterogeneous, inherited neurodegenerative diseases with over-
lapping clinical phenotypes and characterized by defects in initial myelin production
and formation during development [34]. Mutations in genes encoding subunits of the
transcription complex RNA polymerase III (POLR3), namely POLR3A, POLR3B, POLR1C,
POLR3K and POLR3GL might cause a particular type of hypomyelinating leukodystro-
phies known as Pol III-related leukodystrophies [19,35–39]. POL3 is responsible for the
transcription of various non-coding RNAs which have relevant functions in translation
and other biological processes. Dysregulation of POL3 transcribed genes is associated
with a variety of diseases [40]. Recently, Kraoua et al. concluded that imaging findings
were present in the majority of Pol III-related leukodystrophies and could serve a useful
role in the clinical setting to distinguish them among other hypomyelinating disorders
and so guide the molecular diagnostic workup [20]. Advances in molecular genetics have
enabled clinicians to identify more cases having a genetic cause; however, research in the
field has historically suffered from a scarcity of medical and scientific knowledge, and all
those affected face similar challenges in their search for diagnosis, appropriate treatment
and medical care [41]. The management of childhood cerebellar ataxia, a rare condition
with high degree of medical and genetic heterogeneity, warrants a broad, multidisciplinary
and interdisciplinary approach that includes precision medicine [15,42]. Thus, we used a
multi-omics-based approach to diagnose our patient and help advance our understanding
of the disease biology.
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Table 1. Demographic and genetic characteristics of our patient and reported patients with POLR1C mutations.
Patient Family Sex (F/M) Ethnicity Consanguinity
Age at Last
Assessment (Years)
Age of Onset (Years)
Genetic Characteristics
Mutation 1 Mutation 2
Index XXIV F Caucasian (Spanish) No 14 2.5
c.193A>G; c.836G>A;
p.Met65Val p.Arg279Gln
1 [19] I M Libyan Yes 8 0.5
c.95A>T; c.95A>T;
p.Asn32Ile p.Asn32Ile
2 [19] II M Hungarian No 10 1
c.221A>G; c.221A>G;
p.Asn74Ser p.Asn74Ser
3 [19] III M Asian (Chinese) No 4 1
c.436T>C; c.883_885delAAG;
p.Cys146Arg p.Lys295del
4 [19] IV F
Caucasian
(Armenian/Russian) No 6 2.5
c.77C>T; c.326G>A;
p.Thr26Ile p.Arg109His
5 [19] V F Caucasian No 9 1.5
c.193A>G; c.572G>A;
p.Met65Val p.Arg191Gln
6 [19] VI F Caucasian (Turkish) Suspected 18 4
c.326G>A; c.970G>A;
p.Arg109His p.Glu324Lys
7 [19] VII M Caucasian No 33 2
c.395G>A; c.461_462delAA;
p.Gly132Asp p.Lys154Argfs*4
8 [19] VIII F Caucasian No 2 1
c.281T>C; c.785T>C;
p.Val94Ala p.Ile262Thr
9 [20] IX F Tunisian Yes 25 5
c.863T>C; c.863T>C;
p.Phe288Ser p.Phe288Ser






Caucasian No NA 4
c.916_920delTATAT; c.938C>T;
12 [22] M p.Tyr306Leufs*4 p.Thr313Met
13 [22] XII M Caucasian (Dutch) No NA 2
c.193A>G; c.733G>A;
p.Met65Val p.Val245Met
14 [22] XIII F Caucasian (English) No NA 3
c.313A>T; c.916_920delTATAT;
p.Ile105Phe p.Tyr306Leufs*4
15 [22] XIV F Caucasian (English) Yes NA 2
c.836G>A; c.836G>A;
p.Arg279Gln p.Arg279Gln
16 [22] XV F Norwegian No NA 0.3
c.88C>T; c.916_920delTATAT;
p.Pro30Ser p.Tyr306Leufs*4
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Table 1. Cont.
Patient Family Sex (F/M) Ethnicity Consanguinity
Age at Last
Assessment (Years)
Age of Onset (Years)
Genetic Characteristics
Mutation 1 Mutation 2
17 [22] XVI F Caucasian (English) No NA 0
c.221A>G; c.502G>A;
p.Asn74Ser p.Val168Met + splicing error
18 [22] XVII F Caucasian No NA 6
c.79A>G; c.349G>C;
p.Thr27Ala p.Ala117Pro
19 [22] XVIII F Caucasian No NA 0.4
c.322C>T; c.325C>T;
p.His108Tyr p.Arg109Cys
20 [22] XIX F African/American No NA 2
c.70-1G>A; c.835C>T;
p.Asn24Profs27* (prediction) p.Arg279Trp








23 [22] F 0 p.Pro30Ser p.Gln206Lysfs*48





M Asian (Korean) NA NA 5
c.698_699insAA; c.713A>G;
26 [21] F p.Tyr233fs p.Asp238Gly
F: female; M: male; NA: not available.
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Table 2. Clinical characteristics of our patient and reported patients with POLR1C mutations.





















+ 28 + + + + + + 7 + − −
1 [19] Delayed motordevelopment + 22 + + + + − − 3 − + Too young





+ Neverautonomously + + + + + − Always − − Too young
4 [19] Tremor, dysmetria + 15 − + + + − − − * − + Too young
5 [19] Delayed motordevelopment + 24 + + + + − − Always * + − Too young
6 [19] Clumsy gait,frequent falls − 18 + + + + + − 9 (long distances) * + − −
7 [19] Delayed motordevelopment +
Never
autonomously + + + − − + Puberty + − −
8 [19] Delayed motordevelopment + 24 (with support) − + + − − − − − + Too young
9 [20] Tremor, ataxia − 12 − + + + + + 21 * − − −
10 [22] NA NA NA NA + NA + − NA NA − + Too young
11 [22] NA NA NA NA + NA − − NA − − + −
12 [22] NA NA NA NA + NA − − NA − + + −
13 [22] NA NA NA NA + NA − − NA − + − −
14 [22] NA NA NA NA + NA − − NA 12 + + Too young
15 [22] NA NA NA NA + NA + + NA 7 − − Too young
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Table 2. Cont.













(Years) Myopia Dental AbN
Hypogonadotropic
Hypogonadism
16 [22] NA NA NA NA + NA − + NA 0 + + Too young
17 [22] NA NA NA NA + NA + + NA 0 + + Too young
18 [22] NA NA NA NA + NA + − NA − − + −
19 [22] NA NA NA NA + NA + − NA 0 − + −
20 [22] NA NA NA NA + NA + − NA 11 − − Too young
21 [22] NA NA NA NA + NA + + NA 3 + + Too young
22 [22] NA NA NA NA + NA + + NA 4 +C + Too young
23 [22] NA NA NA NA NA NA NA NA NA NA NA − Too young
24 [22] NA NA NA NA + NA − − NA − + + Too young
25 [21] Tremor, ataxia + NA + + + + NA − NA + − −
26 [21] Tremor, ataxia + NA + + + + NA + NA + − −
AbN: abnormalities; +: present; −: absent; NA: not available; C: cataracts.1 General information available for patients 10 to 24 at Gauquelin et al., 2019. * Fast deterioration with infection.
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Table 3. Main MRI characteristics of our patient and reported patients with POLR1C mutations.
Patient Diffuse Hypomyelination Cerebellar Atrophy Thin Corpus Callosum
Index + + +
1 [19] + − +
2 [19] + − +
3 [19] + − +
4 [19] + + +
5 [19] + + +
6 [19] + + +
7 [19] + + +
8 [19] + + +
9 [20] + + +
10 [22] + − +
11 [22] + + +
12 [22] + + +
13 [22] + + +
14 [22] + + +
15 [22] + + +
16 [22] + − −
17 [22] + + +
18 [22] + + +
19 [22] + + +
20 [22] + + +
21 [22] + − +
22 [22] + + +
23 [22] NA NA NA
24 [22] + + +
25 [21] + − NA
26 [21] + − NA
MRI: magnetic resonance imaging; +: present; −: absent; NA: not available.
WES analysis in our patient confirmed two variants in POLR1C. POLR1C mutations
are believed to reduce the transcription of tRNAs or other small noncoding RNAs that
are central to the synthesis of proteins crucial for myelin development in the central
nervous system [19]; however, the molecular mechanisms underlying POLR1C variants
causing hypomyelination remain largely unknown [43]. Although it seems clear that
mutations in Pol III subunits can lead to defects in the enzyme, the precise consequences
of this are difficult to ascertain [40]. To date, 29 pathogenic variants in POLR1C have
been described [22]. WES also revealed a mutation in MMACHC known to be associated
with MAHCC, the most common genetic defect of cobalamin metabolism [32]. To date,
55 mutations have been identified. The mutation in our patient (p.Arg91LysfsTer14) is the
most prevalent worldwide [44,45]. Transcriptome analysis showed increased expression of
POLR1C and MMACHC in our patient. We hypothesized that there could be a compensation
mechanism in place that increases rather than decreases mRNA levels due to the need to
maintain the protein at adequate levels. The appearance of a point mutation, such as the
ones present in our case, does not necessarily mean a decrease in the quantity of mRNA
in the exon. In contrast, if the protein produced is not functional or is truncated, it is
Int. J. Mol. Sci. 2021, 22, 2990 13 of 19
reasonable for an increase in its expression to occur in order to compensate for the levels of
such protein. This upregulation mechanism has been previously described [46,47]; however,
its applicability to this particular case should be further investigated. Transcriptomics
analysis of the differential expression of POLR1C in the patient and her father also revealed
that there was no statistically significant difference in spite of the father’s only presenting
one mutation in the POLR1C gene and not two as the patient did. The upregulation
mechanism hypothesis might also explain why POLR1C expression in the father was
elevated; nonetheless, since the mutation in the father was not accompanied by any other
on that gene, as in the case of the patient, the levels of the protein encoded by POLR1C
in the father could be sufficient for normal function. Although the mother also shared a
POLR1C variant with the patient, she did not show an elevated expression of POLR1C,
whereas the father did. This could be explained by the different clinical significance
of both variants, as annotated in ClinVar (NCBI-NIH) [48]. The POLR1C variant in the
father, rs191582628, is classified as pathogenic or likely pathogenic whereas the variant
present in the mother, rs141471029, showed conflicting interpretations of pathogenicity. In
addition, an untargeted metabolomic approach to a preliminary examination of plausible
functional effects of mentioned mutations, which could also provide further information
for finding potential diagnostic biomarkers, revealed a different metabolic profile in our
patient compared to the healthy control. The main alterations were found in the metabolism
of amino acids, fatty acids and carbohydrates. These results might be relevant since the
nervous system, in particular the cerebellum with its high metabolic demand, is highly
vulnerable to metabolic perturbations. Hence, many disorders of intermediary metabolism
will preferentially target the cerebellum, with ataxia as part of the neurological symptom
complex [49]. The POLR1C gene encodes for the RNA polymerase I and III subunit C,
and the variants found have already been associated with TCS [31] and hypomyelinating
leukodystrophy [19–22]. Among the pathways related to this gene are the RNA polymerase
I Promoter Escape, with a total of 49 genes involved, and ATP/ITP metabolism, with a total
of 85 genes involved (www.genecards.org). Genetic Ontology (GO) annotations related to
this gene include protein dimerization activity and RNA polymerase II activity. Both the
pathways and the activities have implications at the metabolic level [50]. In this work we
shared the complete, raw and unbiased list of metabolites that were altered in our patient
with respect to the control, nonetheless, to define the metabolic implications in the origin or
development of the disease caused by the variants of the POLR1C gene, functional analyses
of the affected pathways are essential.
Compared to studies of single-omics-types, multi-omics provides the opportunity
to draw a comprehensive picture of a disease [51]. In our case, a genetic diagnosis was
reached, but an integrative approach and further molecular and functional studies are
required to achieve a systemic understanding of our patient’s phenotype.
4. Materials and Methods
4.1. Consent and Approval
Informed consent was obtained from all adult participants, and parental permis-
sion and child assent were obtained for child participants. The project was approved by
the Biomedical Research Ethics Committee of the Andalusian Public Health System in
Granada, Spain on 29 October 2015, (project identification code AP163052016). Data record-
ing, sample collection and all in vitro experiments were conducted in accordance with
ethical guidelines following the Nuremberg Code, Belmont Report, and the Declaration
of Helsinki.
4.2. WES for Candidate Gene Identification
A WES analysis was performed for the patient and all available family members. Ge-
nomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany) and the QIAcube instrument (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions, and DNA was sheared to 180–220 bp
Int. J. Mol. Sci. 2021, 22, 2990 14 of 19
fragments with Covaris E220 Focused-ultrasonicator (Covaris, Woburn, MA, USA). Exome
capture and library preparation were performed using 500 ng of sheared original DNA
and an in-solution hybridization technology for target enrichment, Roche NimbleGen
SeqCap EZ MedExome (Roche Sequencing Solutions, Pleasanton, CA, USA), following
the HyperCap Workflow v2.0 (Roche Sequencing Solutions, Pleasanton, CA, USA). The
MedExome design enables the enrichment of medically relevant regions of the human
exome. Exome libraries were sequenced on the NextSeq 500 system (Illumina, San Diego,
CA, USA) using the highest output mode and paired-end 150 bp read lengths. Reads
were aligned to the human reference genome GRCh38 with BWA v0.7.9a [52], SAMtools
v1 (https://github.com/samtools/samtools, accessed on 15 March 2021) [53], Picard v2
(http://broadinstitute.github.io/picard, accessed on 15 March 2021) and Qualimap 2 [54],
and variant calling and filtering was then performed using both the Genome Analysis
Toolkit (GATK) v4 [55,56] and the suggested SAMtools mpileup pipeline [53,57]. Variant
annotation and prioritization was completed following standard guidelines and the AN-
NOVAR tool [58,59], and using Ensembl (https://www.ensembl.org/index.html, accessed
on 15 March 2021) [60] as the primary variant annotation database and PolyPhen-2 [25]
and SIFT [24] as the in silico tools for evaluating the variants’ pathogenicity. In addi-
tion, all variants that produced a change in nucleotide or a change in frameshift were
reviewed and reannotated by in silico analysis on the functional and structural impact
of the SNPs using Ensembl Variant Effect Predictor (VEP) [61], ClinVar (NCBI–NIH) [48]
as well as tools from DAVID Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/,
accessed on 15 March 2021) [62,63] and Ingenuity Pathway Analysis (IPA). Integrative Ge-
nomics Viewer v2.3 (IGV) (https://software.broadinstitute.org/software/igv/, accessed
on 15 March 2021) [64,65] was used to support data visualization and exploration.
4.3. RNA-Seq for Gene Expression Analysis
RNA-seq analysis was performed for the patient and a control sample. The patient’s
fibroblasts were retrieved from a skin biopsy and the control fibroblasts were retrieved
from the HEF line (human foreskin fibroblast cell culture). The fibroblast culture was
maintained in DMEM high glucose medium (Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 10% Fetal Bovine Serum, Glutamine. RNA was extracted from
primary fibroblasts using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Concentration and quality of extracted RNA were
measured using the Qubit 4 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA)
and the 2100 Bioanalyzer Instrument (Agilent Technologies, Santa Clara, CA, USA). Li-
braries from mRNA were prepared using 1 µg of RNA starting material and the TruSeq
Stranded mRNA Library Prep Kit (Illumina, San Diego, CA, USA) according to the man-
ufacturer’s protocol. mRNA libraries were sequenced on the NextSeq 500 system (Illu-
mina, San Diego, CA, USA) using the highest output mode and paired-end 75 bp read
lengths. RNA-Seq data were aligned to the human reference genome GRCh38 by RSEM v1
(https://deweylab.github.io/RSEM/, accessed on 15 March 2021) [66]. Quantification of
sequence alignments was performed at the transcript level using RSEM [66] and differential
gene expression was measured using DESeq (https://www.bioconductor.org/packages/
/2.10/bioc/html/DESeq.html, accessed on 15 March 2021) [67].
4.4. Validation of Next-Generation Sequencing (NGS) Candidate Variants
A small number of identified variants were validated in house through amplification
and Sanger sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo
Fisher Scientific, Waltham, MA, USA) using the capillary electrophoresis instrument ABI
PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were
analyzed using SeqScape Software v2.7.
Transcriptomic analyses were validated using quantitative PCR (qPCR) and specific
primers designed for the study with Primer3 software [68,69] and RNA extracted from
blood samples. Control blood samples came from unaffected family members (parents and
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sibling) and from healthy volunteers matched for weight, sex and age with the patient. RNA
from the patient, controls and unaffected family members was reverse-transcribed into
cDNA using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham,
MA, USA), and then used for qPCR using a QuantStudio 6 Flex Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) with iTaq Universal SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA) according to the manufacturer’s protocol. Quantification
of the fold change in gene expression was determined by relative quantification (RQ;
2−∆∆CT) using the GAPDH and HPRT1 genes as a reference. In addition, transcript isoform
identification was performed in the patient and family members through amplification and
Sanger sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher
Scientific, Waltham, MA, USA) using the ABI PRISM 3130 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). Statistical analyses were made with GraphPad Prism
version 5.0 for Windows (GraphPad Software, La Jolla, CA, USA, www.graphpad.com,
accessed on 1 February 2020). For qPCR analysis, unpaired t-tests were performed to
compare the means of the two groups. Values of ∆∆Ct out of mean ± SD were considered.
4.5. Functional Validation through Metabolomics
4.5.1. Metabolite Extraction and Mass Spectrometry Analysis
Metabolite extraction was performed in plasma and urine samples from the patient
and a healthy control, matched for age, sex and weight, according to standard protocols
with some modifications. The detailed descriptions of the protocols can be found in the
Supplementary Material. Liquid chromatography–mass spectrometry (LC–MS) analyses
were performed using a UHPLC system (Agilent 1290 Infinity LC System, Waldbronn,
Germany) coupled to a LC-QTOF-MS (6520) analyzer (Agilent Technologies, Santa Clara,
CA, USA). Gas chromatography–mass spectrometry (GC–MS) analyses were performed
using a 7890A from Agilent Technologies (Waldbronn, Germany) coupled to an inert
mass spectrometer with triple-Axis detector 5975C (Agilent Technologies, Santa Clara, CA,
USA). Capillary electrophoresis–mass spectrometry (CE–MS) analyses were performed on
a 7100 CE system coupled to a 6224 accurate mass TOF MS (Agilent Technologies, Santa
Clara, CA, USA), equipped with an electrospray ionization (ESI) source.
4.5.2. Data Treatment
LC–MS and CE–MS data were cleaned of background noise and unrelated ions by the
Molecular Feature Extraction (MFE) tool in MassHunter Profinder software B.08.00 (Agilent
Technologies, Santa Clara, CA, USA). Each compound was described by mass, migration
time (MT) (CE–MS) or retention time (RT) (LC–MS), and abundance. Data were filtered
based on their quality assurance. Spectral deconvolution with MassHunter Unknowns
Analysis software version B.08.00 (Agilent Technologies, Santa Clara, CA, USA) was used
to extract the data acquired by GC–MS analysis. Agilent MassHunter Quantitative Analysis
software version B.08.00 was used for the assignment of the target and qualifiers ions, and
peak area integration. Prior to the statistical analysis, sample areas were normalized by
the internal standard abundance. Data were filtered by the coefficient of signal variation
(CV) in QCs. The features or metabolites from the two samples were compared by their
absolutes differences in abundance, and that was expressed as the logarithm base 2 of the
fold change (log2FC). Those features or metabolites having a log2FC ≥ 1.5 were considered
significant and were selected.
4.5.3. Metabolite Identification
Briefly, compound identification from LC–MS and CE–MS data was performed com-
paring accurate m/z outcome measurements against leading online MS databases (METLIN,
KEGG, HMDB and LIPID MAPS) using the CEU Mass Mediator tool. The identification
of m/z was performed considering each of the possible adducts as described for MFE.
Compound identification from GC–MS data was performed with the Fiehn library version
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2008 and the CEMBIO in-house spectral library, and always by comparing both RT and
spectra extracted during the deconvolution against each compound included in the library.
Additional information on the untargeted metabolomics methodology is provided in
the Supplementary Material.
5. Conclusions
Our findings add evidence to the genetic spectrum of POLR3-related leukodystrophy
caused by POLR1C mutations [19–22]. The data reported here reinforced the association
between POLR1C mutations and hypomyelinating leukodystrophy and emphasized the
relevance of combining clinical features, characteristic MRI patterns, and multi-omics to
reach a definitive diagnosis in undiagnosed cases presenting hypomyelination and ataxia.
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